Literature DB >> 35590014

Truncating TINF2 p.Tyr312Ter variant and inherited breast cancer susceptibility.

Susanna Koivuluoma1, Sandra Vorimo1, Tiina M Mattila1, Anna Tervasmäki1, Timo Kumpula1, Outi Kuismin2, Robert Winqvist1, Jukka Moilanen2, Tuomo Mantere1, Katri Pylkäs3.   

Abstract

TINF2 is a critical subunit of the shelterin complex, which protects and maintains the length of telomeres. Pathogenic missense and truncating TINF2 mutations are causative for dyskeratosis congenita (DC), a rare, dominantly inherited bone marrow failure syndrome characterized by mucocutaneous abnormalities and cancer predisposition. Recent reports indicate that specific TINF2 truncating mutations act as high penetrance cancer predisposition alleles outside DC context, including breast cancer in their tumor spectrum. Here, we have evaluated the role of germline mutations in TINF2 and other shelterin genes in inherited breast cancer susceptibility using exome sequencing data from 98 Northern Finnish breast cancer cases with indication of inherited disease predisposition as a discovery cohort. A single protein truncating variant, TINF2 p.Tyr312Ter, was identified in one of the cases (1/98), and four more carriers were observed in the subsequently genotyped unselected breast cancer cohort (4/1904). None of the carriers were reported to have DC. TINF2 p.Tyr312Ter resulted in stable short form of mRNA transcript, and normal telomere length has been indicated by a recent report. Although recurrent in cases (total of 5/2095), TINF2 p.Tyr312Ter is also present in Finnish population controls (8/12,517), and the observed 4-fold higher frequency in cases falls at most into the range of moderate breast cancer risk alleles (OR 3.74, 95% CI 1.22-11.45, p = 0.029). Current results indicate that not all TINF2 truncating variants are high cancer risk alleles and add further evidence that different TINF2 mutations can have very diverse effects on the disease phenotype.
© 2022. The Author(s).

Entities:  

Keywords:  Breast cancer; Dyskeratosis congenita; Hereditary predisposition; TINF2

Year:  2022        PMID: 35590014     DOI: 10.1007/s10689-022-00295-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  6 in total

1.  A Truncating Germline Mutation of TINF2 in Individuals with Thyroid Cancer or Melanoma Results in Longer Telomeres.

Authors:  Huiling He; Wei Li; Daniel F Comiskey; Sandya Liyanarachchi; Taina T Nieminen; Yanqiang Wang; Katherine E DeLap; Pamela Brock; Albert de la Chapelle
Journal:  Thyroid       Date:  2020-02       Impact factor: 6.568

2.  Exome sequencing identifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer.

Authors:  Susanna Koivuluoma; Anna Tervasmäki; Saila Kauppila; Robert Winqvist; Timo Kumpula; Outi Kuismin; Jukka Moilanen; Katri Pylkäs
Journal:  Eur J Cancer       Date:  2020-12-03       Impact factor: 9.162

3.  Three novel truncating TINF2 mutations causing severe dyskeratosis congenita in early childhood.

Authors:  G S Sasa; A Ribes-Zamora; N D Nelson; A A Bertuch
Journal:  Clin Genet       Date:  2011-04-07       Impact factor: 4.438

4.  A novel form of the telomere-associated protein TIN2 localizes to the nuclear matrix.

Authors:  Patrick G Kaminker; Sahn-Ho Kim; Pierre-Yves Desprez; Judith Campisi
Journal:  Cell Cycle       Date:  2009-03-26       Impact factor: 5.173

5.  TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.

Authors:  Amanda J Walne; Tom Vulliamy; Richard Beswick; Michael Kirwan; Inderjeet Dokal
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

6.  Evidence for common short natural trans sense-antisense pairing between transcripts from protein coding genes.

Authors:  Ping Wang; Shanye Yin; Zhenguo Zhang; Dedong Xin; Landian Hu; Xiangyin Kong; Laurence D Hurst
Journal:  Genome Biol       Date:  2008-12-02       Impact factor: 13.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.